S
75.01
-0.06 (-0.08%)
前收盘价格 | 75.07 |
收盘价格 | 74.75 |
成交量 | 517,625 |
平均成交量 (3个月) | 1,283,452 |
市值 | 3,780,046,592 |
股市价格/股市净资产 (P/B) | 14.92 |
52周波幅 | |
利润日期 | 5 Aug 2025 - 11 Aug 2025 |
稀释每股收益 (EPS TTM) | -4.38 |
总债务/股东权益 (D/E MRQ) | 21.55% |
流动比率 (MRQ) | 15.68 |
营业现金流 (OCF TTM) | -69.10 M |
杠杆自由现金流 (LFCF TTM) | -7.47 M |
资产报酬率 (ROA TTM) | -45.06% |
股东权益报酬率 (ROE TTM) | -87.35% |
市场趋势
短期 | 中期 | ||
行业 | Biotechnology (US) | 看跌 | 看跌 |
Biotechnology (全球的) | 看跌 | 看跌 | |
股票 | Soleno Therapeutics, Inc. | 看跌 | 看涨 |
AIStockmoo 评分
1.4
分析师共识 | 2.0 |
内部交易活动 | NA |
价格波动 | -3.0 |
技术平均移动指标 | 2.5 |
技术振荡指标 | 4.0 |
平均 | 1.38 |
Soleno Therapeutics Inc is focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its product candidates comprise Diazoxide Choline Controlled-Release tablets, which is an oral tablet for the treatment of Prader-Willi Syndrome. DCCR tablets consist of the active ingredient diazoxide choline, a choline salt of diazoxide, which is a benzothiadiazine. |
|
部门 | Healthcare |
行业 | Biotechnology |
投资方式 | Small Growth |
内部持股比例 | 2.40% |
机构持股比例 | 103.27% |
52周波幅 | ||
目标价格波幅 | ||
高 | 145.00 (Piper Sandler, 93.31%) | 购买 |
中 | 105.00 (39.98%) | |
低 | 97.00 (Guggenheim, 29.32%) | 购买 |
平均值 | 111.86 (49.13%) | |
总计 | 7 购买 | |
平均价格@调整类型 | 71.97 |
公司 | 日期 | 目标价格 | 调整类型 | 价格@调整类型 |
---|---|---|---|---|
Baird | 08 May 2025 | 105.00 (39.98%) | 购买 | 76.26 |
27 Mar 2025 | 102.00 (35.98%) | 购买 | 67.39 | |
Guggenheim | 08 May 2025 | 97.00 (29.32%) | 购买 | 76.26 |
28 Mar 2025 | 81.00 (7.99%) | 购买 | 71.99 | |
Piper Sandler | 24 Apr 2025 | 145.00 (93.31%) | 购买 | 74.23 |
HC Wainwright & Co. | 15 Apr 2025 | 100.00 (33.32%) | 购买 | 70.25 |
31 Mar 2025 | 100.00 (33.32%) | 购买 | 71.45 | |
Stifel | 28 Mar 2025 | 108.00 (43.98%) | 购买 | 71.99 |
05 Mar 2025 | 74.00 (-1.35%) | 购买 | 44.99 | |
Cantor Fitzgerald | 27 Mar 2025 | 123.00 (63.98%) | 购买 | 67.39 |
Laidlaw & Co. | 27 Mar 2025 | 105.00 (39.98%) | 购买 | 67.39 |
显示更多 |
该时间范围内无数据。
支撑、阻力和趋势线水平是由人工智能(AI)模型生成的,请谨慎解读。
投资组合